A first-class contract development and manufacturing organization (CDMO), Rottendorf Pharma has been manufacturing, packaging, developing formulations and analytical methods for solid oral dosage forms for the global pharmaceutical industry for more than 90 years. The company produces more than 600 originator and generic drug products annually for big, small, virtual, and global pharmaceutical and biotechnology companies.
Rottendorf Pharma operates by the philosophy of TOTAL PROCESS OWNERSHIP (TPO) and TOTAL TECHNOLOGICAL MASTERING (TTM), in which we work as an extension of clients’ organizations. Therefore leveraging our expertise to optimize solid dosage form production for our customers' benefit. TPO and TTM reduce clients’ management oversight requirements and costs while improving the supply chain and product quality. As our business strategy, Rottendorf Pharma has neither our own product brands in the market nor holds any product licenses, and therefore we are never in competition with their clients.
Rottendorf Pharma invests in state-of-the-art facilities, featuring best-in-class equipment and technologies, and staffed with over 900 experienced, skilled workers, including many formulation scientists. In our German facilities, compliant with GMP, FDA, ANVISA, and others, the originator and generic drug products are manufactured, packaged and developed. Clients choose Rottendorf Pharma for our broad-ranging expertise, global regulatory capabilities, commitment to quality, state-of-the-art facilities, and exceptional customer service. As an example, this has been recognized with five CMO Leadership Awards in 2015 for excellence in regulatory, quality, innovation, and productivity.